SREBF2 and cancer: Cleavage of SREBP2 from the ER by Caspase-3 (CASP3) activates cholesterol biosynthesis, subsequently activating the sonic hedgehog signaling pathway, which renders cancer stem cell populations in HCC resistant to sorafenib and lenvatinib treatment (Mok et al., 2022).